Proper technique for using the dry powder inhaler (often an Ellipta inhaler) is critical to ensure the medication reaches your lungs effectively. Your doctor or pharmacist will demonstrate the correct method.

• Do Not Shake: Unlike metered-dose inhalers, the Ellipta inhaler should not be shaken.
• Prepare the Dose: Slide the cover down until you hear a “click.” This prepares the dose. Do not close the cover until after you have inhaled the medicine, as this will waste the dose.
• Breathe Out Fully: Hold the inhaler away from your mouth and breathe out completely.
• Inhale Deeply: Place your lips firmly around the mouthpiece. Take one long, steady, deep breath in through your mouth. Do not breathe in through your nose.
• Hold Your Breath: Remove the inhaler from your mouth and hold your breath for about 3-4 seconds, or as long as comfortably possible.
• Breathe Out Gently: Breathe out slowly and gently, away from the inhaler.
• Close and Rinse: Slide the cover upwards until it clicks closed. After inhaling, rinse your mouth with water and spit it out without swallowing. This helps to prevent oral thrush (a fungal infection).
• The dose counter on the inhaler will show how many doses are left.

The strength of this medication lies in its triple action, with each component targeting a different aspect of airway constriction and inflammation. This multi-pronged approach provides broader and more effective control over respiratory symptoms.

• Fluticasone (Inhaled Corticosteroid – ICS): This component reduces inflammation in the airways. It decreases swelling and mucus production in the lungs, which are common issues in COPD and asthma. By calming the inflammatory response, it helps to prevent airway narrowing over time.
• Umeclidinium (Long-Acting Muscarinic Antagonist – LAMA): This is a bronchodilator. It works by blocking certain natural substances (acetylcholine) that cause the muscles around the airways to tighten. By blocking these signals, umeclidinium helps the airways to relax and stay open, making breathing easier. Its effects last for 24 hours.
• Vilanterol (Long-Acting Beta2-Agonist – LABA): This is also a bronchodilator. It works by stimulating specific receptors in the lungs that cause the muscles around the airways to relax. This relaxation widens the airways, improving airflow. Vilanterol also provides a sustained bronchodilating effect for 24 hours.
• Together, these three components reduce inflammation and keep the airways open, leading to improved breathing, reduced symptoms like coughing and wheezing, and fewer flare-ups.

Like all medications, Fluticasone, umeclidinium, and vilanterol can cause side effects, although not everyone experiences them. Most common side effects are mild, but some can be serious.

• Common Side Effects:
  • Oral Thrush (Candidiasis): Fungal infection in the mouth or throat, preventable by rinsing the mouth after use.
  • Headache: A frequently reported side effect.
  • Upper Respiratory Tract Infections: Such as colds or flu-like symptoms, sore throat.
  • Hoarseness or Voice Changes: Due to the inhaled corticosteroid.
  • Cough: Can occur.
• Serious Side Effects (less common but require immediate medical attention):
  • Pneumonia: Increased risk, especially in COPD patients. Watch for fever, chills, increased cough, or changes in mucus.
  • Paradoxical Bronchospasm: Sudden worsening of breathing immediately after inhalation.
  • Cardiovascular Effects: Increased blood pressure, fast or irregular heartbeat, chest pain.
  • Adrenal Suppression: Weakened adrenal gland function, especially when transitioning from oral steroids.
  • Eye Problems: Glaucoma or cataracts with long-term use.
  • Urinary Retention: Difficulty urinating.
  • Allergic Reactions: Rash, hives, swelling of face/mouth/tongue, difficulty breathing.

Before and during treatment with Fluticasone, umeclidinium, and vilanterol, it’s vital to be aware of specific warnings and precautions to ensure safe and effective use.

• Not for Acute Symptoms: This medication is for long-term maintenance and should NOT be used for sudden or worsening breathing problems. Always have a fast-acting rescue inhaler (e.g., albuterol) available for acute attacks.
• Do Not Use with Other LABA/LAMA: Avoid using additional medicines that contain a long-acting beta2-agonist or a long-acting muscarinic antagonist, as this could lead to an overdose.
• Infections: Use with caution if you have untreated infections, especially tuberculosis, herpes simplex, or any other viral, bacterial, or fungal infections. Inhaled corticosteroids can weaken the immune system.
• Cardiovascular Conditions: Use with caution if you have heart problems, including irregular heartbeats or high blood pressure, as vilanterol can affect the heart.
• Eye and Urinary Conditions: Use with caution if you have narrow-angle glaucoma or urinary retention (e.g., due to an enlarged prostate), as umeclidinium can worsen these conditions. Regular eye exams are recommended for long-term users.
• Bone Mineral Density: Long-term use of inhaled corticosteroids may rarely lead to a decrease in bone mineral density.
• Diabetes: Monitor blood sugar levels closely, as corticosteroids can sometimes increase blood glucose.

• r a missed one.
• Drug Interactions: While generally safe, certain medications can interact with this combination.
  • Strong CYP3A4 Inhibitors: Medications like ritonavir (for HIV) or ketoconazole (for fungal infections) can increase the levels of fluticasone and vilanterol in the body, potentially leading to more systemic side effects.
  • Other LABAs or LAMAs: Do not use this medication with other long-acting beta2-agonists or long-acting muscarinic antagonists, as this can increase the risk of overdose and severe side effects.
  • Beta-blockers: These can reduce the effectiveness of vilanterol.
• Always inform your doctor and pharmacist about all medications, supplements, and herbal remedies you are currently taking.

The specific dosage guidelines for Fluticasone, umeclidinium, and vilanterol are straightforward due to its once-daily nature, but adherence to these guidelines is paramount for effective management.

• Once Daily: The standard and maximum recommended dose is one inhalation per day, at the same time each day.
• Strength: It typically comes in specific strengths, for example, 100/62.5/25 mcg (fluticasone/umeclidinium/vilanterol) for COPD, and possibly 200/62.5/25 mcg for asthma, depending on severity and previous therapy.
• COPD: For maintenance treatment of COPD, the 100/62.5/25 mcg strength is commonly indicated.
• Asthma: For asthma maintenance, either the 100/62.5/25 mcg or 200/62.5/25 mcg strength may be prescribed based on the patient’s asthma severity and history.
• No Dosage Adjustment: No dosage adjustments are typically needed for elderly patients or those with kidney impairment. Caution is advised for those with moderate to severe liver impairment.
• Continuous Use: This medication must be used regularly, every day, even when symptoms improve, to maintain long-term control and prevent exacerbations. Do not stop without consulting your doctor.

Fluticasone, umeclidinium, and vilanterol is a prescription-only medication. It cannot be obtained without a valid prescription from a qualified healthcare professional.

• Medical Evaluation: A thorough medical evaluation, including a diagnosis of COPD or asthma, is necessary before this medication can be prescribed. The doctor will assess your lung function, symptom severity, and medical history.
• Specific Indication: This triple therapy is typically reserved for patients with moderate to severe COPD, or adults with asthma who are not adequately controlled on dual therapy or require multiple medications.
• Inhaler Training: Due to the specific technique required for the Ellipta inhaler, your doctor or pharmacist will provide comprehensive training on its correct use.
• Regular Monitoring: Ongoing medical supervision and regular follow-up appointments are essential to monitor your response to the medication, assess for side effects, and adjust your treatment plan as needed.
• Rescue Inhaler: Your doctor will also prescribe a separate short-acting rescue inhaler for immediate relief of sudden breathing problems, emphasizing that this triple therapy is not for acute attacks.

1. What is this combination used for? To treat COPD and asthma by improving lung function and reducing symptoms like wheezing and breathlessness.

2. What drug classes are included?

• Fluticasone: Inhaled corticosteroid (ICS)

• Umeclidinium: Long-acting muscarinic antagonist (LAMA)

• Vilanterol: Long-acting beta2 agonist (LABA).

3. Is it a controlled substance? No, it is not classified as a controlled substance.

4. Is it available in generic form? No, currently only available as Trelegy Ellipta.

5. What form and strength is available? Dry powder inhaler:

• Fluticasone furoate 100 mcg

• Umeclidinium 62.5 mcg

• Vilanterol 25 mcg per inhalation.

6. How is it administered? One inhalation once daily using the Ellipta device.

7. What age group is it approved for? Adults with COPD; adults and children ≥18 years for asthma.

8. What are common side effects? Headache, sore throat, cough, upper respiratory infections, and hoarseness.

9. Can it cause serious reactions? Yes—pneumonia, glaucoma, osteoporosis, adrenal suppression, and paradoxical bronchospasm.

10. Is it safe during pregnancy? Use only if clearly needed; consult a healthcare provider.

11. Can it be used with rescue inhalers? Yes, but it does not replace fast-acting bronchodilators.

12. How long does it take to work? Improvement may be seen within days; full effect in several weeks.

13. Is a prescription required? Yes, it is prescription-only.

14. Is it available in Pakistan? Yes, under brand name Trelegy Ellipta or imported equivalents.

15. Can it be used long-term? Yes, for maintenance therapy in asthma and COPD.

16. What makes it different from dual inhalers? It combines ICS + LAMA + LABA in one device for once-daily dosing.

17. Is it used for acute asthma attacks? No, it is not a rescue medication.

18. Can it be used with other asthma medications? Yes, often alongside leukotriene inhibitors or rescue inhalers.

19. What monitoring is needed? Lung function tests, eye exams, bone density, and adrenal function.

20. What should be avoided during use? Smoking, abrupt discontinuation, and sharing inhalers.